Recordati SpA (WBO:REC) Loans Receivable : €0 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Recordati SpA Loans Receivable?

Recordati SpA's Loans Receivable for the quarter that ended in Dec. 2023 was €0 Mil.

Recordati SpA Loans Receivable Historical Data

The historical data trend for Recordati SpA's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA Loans Receivable Chart

Recordati SpA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Loans Receivable

Get a 7-Day Free Trial

Recordati SpA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Recordati SpA Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Recordati SpA Loans Receivable Related Terms

Thank you for viewing the detailed overview of Recordati SpA's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Recordati SpA (WBO:REC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (WBO:REC) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

RICFY:USA REC:Italy RECm:UK 0KBS:UK RER1:Germany

Address

Via Matteo Civitali 1, MIlan, ITA, 20148

Website

https://www.recordati.com

Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.